Co-expression of KIT receptor and its ligand stem cell factor in merkel cell carcinoma

Dermatology

Volumn 218, Issue 1, 2008, Pages 37-43

  Krasagakis, Konstantin ^a   Krüger Krasagakis, Sabine ^a   Eberle, Jürgen ^b   Tsatsakis, Aristidis ^a   Tosca, Androniki D ^a   Stathopoulos, Efstathios N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Autocrine; KIT; Merkel cell carcinoma; Proliferation; Stem cell factor

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; STEM CELL FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MERKEL CELL TUMOR; NICK END LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, MERKEL CELL; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; STEM CELL FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 58149097465     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173704     Document Type: Article

References (40)

1. Hitchcock CL, Bland KI, Laney RG, Franzini D, Harris B, Copeland EM: Neuroendocrine (Merkel cell) carcinoma of the skin: its natural history, diagnosis, and treatment. Ann Surg 1988;207:201-207.
2. Krasagakis K, Tosca AD: Overview of Merkel cell carcinoma and recent advances in research. Int J Dermatol 2003;42:669-676.
3. Hodgson NC: Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4.
4. Voog E, Biron P, Martin JP, Blay JY: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999;85:2589-2595.
5. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000;18:2493-2499.
6. Poulsen M: Merkel-cell carcinoma of the skin. Lancet Oncol 2004;5:593-599.
7. Collins I, Workman P: New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700.
8. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
9. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-421.
10. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037-1051.
11. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH: Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991;10:4121-4128.
12. Roskoski R Jr: Signaling by Kit protein-tyrosine kinase: the stem cell factor receptor. Biochem Biophys Res Commun 2005;337:1-13.
13. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-376.
14. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U: Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 2001;61:2200-2206.
15. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
16. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
17. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R: CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol 2002;24:289-293.
18. Grichnik JM, Ali WN, Burch JA, Byers JD, Garcia CA, Clark RE, Shea CR: KIT expression reveals a population of precursor melanocytes in human skin. J Invest Dermatol 1996;106:967-971.
19. Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA: Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene: implications for treatment with imatinib mesylate. J Cutan Pathol 2007;34:324-329.
20. Hausschild A, Garbe C: Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma): Quality Assurance Committee of the German Society of Dermatology and Professional Organization of German Dermatologists e.V. Hautarzt 1998;48(suppl 1):27-29.
21. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-140.
22. Hines SJ, Organ C, Kornstein MJ, Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995;6:769-779.
23. Rygaard K, Nakamura T, Spang-Thomsen M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993;67:37-46.
24. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994;54:3049-3053.
25. Sheu LF, Lee WC, Lee HS, Kao WY, Chen A: Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium. J Pathol 2005;207:216-223.
26. Théou-Anton N, Tabone S, Brouty-Boyé D, Saffroy R, Ronnstrand L, Lemoine A, Emile JF: Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006;94:1180-1185.
27. Kartha RV, Sundram UN: Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis. Modern Pathol 2008;21:96-104.
28. Feinmesser M, Halpern M, Kaganovsky E, Brenner B, Fenig E, Hodak E, Sulkes J, Okon E: c-kit expression in primary and metastatic merkel cell carcinoma. Am J Dermatopathol 2004;26:458-462.
29. Llombart B, Monteagudo C, López-Guerrero JA, Carda C, Jorda E, Sanmartín O, Almenar S, Molina I, Martín JM, Llombart-Bosch A: Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 2005;46:622-634.
30. Strong S, Shalders K, Carr R, Snead DR: KIT receptor (CD117) expression in Merkel cell carcinoma. Br J Dermatol 2004;150:384-385.
31. Fenig E, Nordenberg J, Beery E, Sulkes J, Wasserman L: Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol Rep 2004;11:213-217.
32. Nishio M, Oda A, Koizumi K, Satoh I, Sato Y, Endoh T, Tsutsumi A, Fujihara M, Ikebuchi K, Ikeda H, Koike T, Sawada KI: Stem cell factor prevents Fas-mediated apoptosis of human erythroid precursor cells with Src-family kinase dependency. Exp Hematol 2001;29:19-29.
33. Chung IJ, Dai C, Krantz SB: Stem cell factor increases the expression of FLIP that inhibits IFN-gamma-induced apoptosis in human erythroid progenitor cells. Blood 2003;101:1324-1328.
34. Pozo L, Sanchez-Carrillo JJ, Martinez A, Blanes A, Diaz-Cano SJ: Differential kinetic features by tumour topography in cutaneous small-cell neuroendocrine (Merkel cell) carcinomas. J Eur Acad Dermatol Venereol 2007;21:1220-1228.
35. Koljonen V, Tukiainen E, Haglund C, Böhling T: Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathology 2006;49:551-553.
36. Tucci MG, Lucarini G, Giangiacomi M, Zizzi A, Criante P, Ricotti G, Biagini G: Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma. J Eur Acad Dermatol Venereol 2006;20:1220-1225.
37. Yee NS, Hsiau CW, Serve H, Vosseller K, Besmer P: Mechanism of down-regulation of c-kit receptor: roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J Biol Chem 1994;269:31991-31998.
38. Kondapalli L, Soltani K, Lacouture ME: The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 2005;53:291-302.
39. Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A: The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008;216:109-117.
40. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.